- SFL Corporation Ltd (NYSE:SFL) reported second-quarter operating revenue growth of 0.6% Q/Q to $153.3 million, beating the consensus of $149.65 million.
- EPS was $0.45 for the quarter, compared to $0.37 in Q1.
- Operating income increased to $76.31 million (+28.6% Q/Q), and margin improved to 49.8% from 38.9% last quarter.
- The company received a charter hire of ~$164.9 million in the quarter from the company’s vessels and rigs.
- SFL reported Adjusted EBITDA of $115.8 million from consolidated subsidiaries, plus an additional $7.8 million adjusted EBITDA from associated companies.
- “So far in 2022 we have added approximately $1.3 billion to our fixed-rate backlog, with several new bluechip customers, such as Trafigura, Hapag-Lloyd, ConocoPhillips and most recently Koch Industries, with the addition of four modern, eco-design vessels,” commented Ole B. Hjertaker, CEO of SFL.
- Dividend: SFL declared a quarterly cash dividend of $0.23 per share, payable on September 29, to shareholders on record as of September 15, and the ex-dividend date of September 14, 2022.
- As of June 30, 2022, and adjusted for subsequent transactions, the estimated fixed-rate charter backlog from the company’s fleet of 75 wholly or partly owned vessels and newbuilding under construction was ~$3.7 billion with a weighted remaining charter term of 6.8 years.
- As of June 30, 2022, SFL had ~$224 million in cash and equivalents.
- Price Action: SFL shares are trading higher by 6.91% at $11.29 on the last check Wednesday.
Virios Therapeutics’ Announced Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM"), today announced commencement of enrollment in its exploratory Long-COVID trial.
